What do systematic reviews say?

Levamisole vs steroids or placebo or both, or no treatment

Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.52 [0.33, 0.82]
  8 studies · 474 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.65 [0.48, 0.88]
  8 studies · 462 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Levamisole vs steroids or placebo or both, or no treatment

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Very low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 4.18 [0.72, 24.21]
  3 studies · 214 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 3 [0.13, 71.92]
  1 study · 100 participants
  Low